REVIVA PHARMACEUTICALS HOLDINGS, INC.

Listed Company

RVPHCIK 0001742927NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-19.90M

Total Assets

$15.92M

Equity

$8.65M

Shares Out

12.81M

Op. Cash Flow

$-24.59M

Business

REVIVA PHARMACEUTICALS HOLDINGS, INC. is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases with significant unmet medical needs. It develops new chemical entities using a chemical genomics-driven technology platform and proprietary chemistry, with a pipeline focused on central nervous system, inflammatory, and cardiometabolic diseases. Key activities include in-house drug discovery and clinical development, currently centered on lead candidate brilaroxazine (RP5063) and second candidate RP1208. The company conducts global clinical trials and holds composition-of-matter patents in the U.S., Europe, and other countries.

Summary from filing dated 2025-04-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	12	23	31	23	5
General and administrative	8	8	8	5	5
Total operating expenses	20	31	40	28	10
Loss from operations	−20	−31	−40	−28	−10
Gain on remeasurement of warrant liabilities	89,010	717,645	−239,216	−194,709	2
Interest expense	−13,402	−18,497	−33,725	—	—
Interest income	311,370	361,369	398,413	—	—
Other expense, net	−32,960	−160,916	134,276	—	—
Total other income, net	354,018	899,601	259,748	−11,907	2
Loss before provision for income taxes	−20	−30	−39	−28	−9
Provision for income taxes	18,889	19,514	16,949	−20,777	6,004
Net loss	−20	−30	−39	−28	−9
Basic and diluted (in dollars per share)	−5.48	−17.73	−1.65	−1.45	−0.58
Basic and diluted (in shares)	4	2	24	20	15

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-09-30	FY 2023 2023-06-30
Cash and cash equivalents	14	13	23	—	—
Prepaid clinical trial costs	0	540,601	78,295	—	—
Prepaid expenses and other current assets	664,685	666,435	254,637	—	—
Total current assets	15	15	24	—	—
Non-current prepaid clinical trial costs	819,721	819,721	0	—	—
Total Assets	16	16	24	—	—
Short-term debt	406,875	458,154	0	—	—
Accounts payable	3	6	4	—	—
Accrued clinical expenses	3	7	—	—	—
Accrued compensation	485,899	635,587	958,607	—	—
Other accrued liabilities	791,611	500,616	400,490	—	—
Total current liabilities	7	15	17	17	13
Warrant liabilities	0	89,010	806,655	—	—
Total Liabilities	7	15	18	18	14
Commitments and Contingencies	—	—	—	—	—
Common stock, par value of $0.0001; 515,000,000 and 315,000,000 shares authorized; 5,842,497 and 2,328,960 shares issued and outstanding as of December 31, 2025 and 2024, respectively	11,655	4,658	2,792	—	—
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and 2024	0	0	0	—	—
Additional paid-in capital	193	165	140	—	—
Accumulated deficit	−184	−164	−134	−125	−114
Total stockholders' equity	9	812,572	6	−13	−2
Total Liabilities and Stockholders Equity	16	16	24	—	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Change in fair value of warrant liabilities	−89,010	−717,645	239,216	194,709	−2
Stock-based compensation expense	2	2	3	176,735	106,713
Prepaid clinical trial costs (current and non-current)	540,601	−1	186,288	—	—
Prepaid expenses and other current assets	1,750	−411,798	−115,401	1	−2
Accounts payable	−3	2	328,837	3	−498,463
Accrued expenses and other current liabilities	−4	−5	7	5	2
Net cash used in operating activities	−25	−34	−28	−19	−11
Proceeds from issuance of short-term debt	406,875	976,904	667,500	0	—
Repayment of short-term debt	−458,154	−518,750	−667,500	0	—
Proceeds from issuance of common stock, common stock warrants, prefunded warrants and from modification of existing warrants, in offerings, net of transaction costs	17	23	27	8	31
Net cash provided by financing activities	26	24	33	8	32
Net decrease in cash and cash equivalents	962,461	−10	5	−11	21
Cash paid for taxes	3,369	3,417	19,754	16,484	2,400
Cash paid for interest	13,402	18,497	30,622	0	0
Settlement of bonuses in form of stock options	0	330,816	0	—	—
Warrant modification recorded in stockholders' equity	0	1	0	—	—
Transaction costs related to offerings included in accounts payable and accrued expenses	136,267	143,136	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro